Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib

@article{Mller2011CosteffectivenessON,
  title={Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib},
  author={J. M{\"o}ller and L. Nicklasson and A. Murthy},
  journal={Journal of Medical Economics},
  year={2011},
  volume={14},
  pages={690 - 697}
}
Abstract Objective: To estimate the cost-effectiveness (cost per additional life-year [LY] and quality-adjusted life-year [QALY] gained) of lenalidomide plus dexamethasone (LEN/DEX) compared with bortezomib for the treatment of relapsed-refractory multiple myeloma (rrMM) in Norway. Methods: A discrete-event simulation model was developed to predict patients’ disease course using patient data, best response, and efficacy levels obtained from LEN/DEX MM-009/-010 trials and the bortezomib (APEX… Expand
Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients
...
1
2
3
4
...

References

SHOWING 1-10 OF 41 REFERENCES
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Biology and therapy of multiple myeloma in 1996.
...
1
2
3
4
5
...